Medically reviewed by Drugs.com. Last updated on Mar 20, 2019.
(doo PIL ue mab)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution Prefilled Syringe, Subcutaneous [preservative free]:
Dupixent: 300 mg/2 mL (2 mL); 200 mg/1.14 mL (1.14 mL) [contains polysorbate 80]
Brand Names: U.S.
- Interleukin-4 Receptor Antagonist
- Monoclonal Antibody
- Monoclonal Antibody, Anti-Asthmatic
Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by binding to the IL-4Rα subunit. Blocking IL-4Rα with dupilumab inhibits IL-4 and IL-13 cytokine-induced inflammatory responses, including the release of proinflammatory cytokines, chemokines, nitric oxide and IgE; however, the mechanism of dupilumab action in asthma has not been definitively established.
Vd: ~4.8 ± 1.3 L
Monoclonal antibodies are primarily degraded into small peptides and amino acids by catabolism
Clearance: The median time to non-detectable concentrations is 10 to 11 weeks (for 300 mg every 2 weeks), 13 weeks (for 300 mg weekly), and 9 weeks (for 200 mg every 2 weeks). Age did not affect clearance.
Time to Peak
Special Populations Note
Weight: Dupilumab trough concentrations were lower in subjects with higher body weight.
Use: Labeled Indications
Asthma: Add-on maintenance treatment of moderate to severe asthma in adults and pediatric patients ≥12 years of age with an eosinophilic phenotype or with corticosteroid dependent asthma
Limitations of use: Not indicated for the relief of acute bronchospasm or status asthmaticus.
Atopic dermatitis: Treatment of moderate to severe atopic dermatitis in adults and pediatric patients ≥12 years of age whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
Rhinosinusitis (chronic) with nasal polyposis: Add-on maintenance treatment in adults with inadequately controlled chronic rhinosinusitis with nasal polyposis
Known hypersensitivity to dupilumab or any component of the formulation
Asthma, moderate to severe: SubQ:
Initial: 400 mg (given as two 200 mg injections) or 600 mg (given as two 300 mg injections).
Maintenance: 200 mg (following 400 mg initial dose) or 300 mg (following 600 mg initial dose) once every other week.
Asthma, oral corticosteroid dependent or with comorbid moderate to severe atopic dermatitis: SubQ:
Initial: 600 mg (given as two 300 mg injections).
Maintenance: 300 mg once every other week.
Atopic dermatitis: SubQ:
Initial: 600 mg (given as two 300 mg injections).
Maintenance: 300 mg once every other week.
Rhinosinusitis (chronic) with nasal polyposis: SubQ: 300 mg once every other week.
Missed doses: If a dose is missed, administer within 7 days from the missed dose and then resume the original schedule. If the missed dose is not administered within 7 days, wait until the next dose on the original schedule.
Refer to adult dosing.
Asthma (moderate to severe), maintenance treatment:
Children ≥12 years and Adolescents: SubQ: Initial: 400 mg once (administered as two 200 mg injections), followed by a maintenance dose of 200 mg every other week or 600 mg once (administered as two 300 mg injections), followed by a maintenance dose of 300 mg every other week.
Corticosteroid-dependent asthma or comorbid atopic dermatitis (moderate to severe in patients ≥18 years): SubQ: Initial: 600 mg once (administered as two 300 mg injections), followed by a maintenance dose of 300 mg every other week.
Atopic dermatitis (AD), moderate to severe:
Children ≥12 years and Adolescents ≤17 years:
<60 kg: SubQ: Initial: 400 mg once (administered as two 200 mg injections), followed by a maintenance dose of 200 mg every other week.
≥60 kg: SubQ: Initial: 600 mg once (administered as two 300 mg injections), followed by a maintenance dose of 300 mg every other week.
Adolescents ≥18 years: SubQ: Initial: 600 mg once (administered as two 300 mg injections), followed by a maintenance dose of 300 mg every other week.
SubQ: Administer as a subcutaneous injection into the thigh or lower abdomen (avoiding areas within 2 inches of navel); caregiver may administer in upper arm. Rotate injection sites, including initial doses (administer 600 mg initial dose as two 300 mg injections; administer 400 mg initial dose as two 200 mg injections). Do not administer into skin that is tender, damaged, bruised, or scarred. Patients may self-administer injection after proper training. Allow solution to reach room temperature for 45 minutes (300 mg prefilled syringe) or 30 minutes (200 mg prefilled syringe) prior to use; do not remove needle cap while allowing product to reach room temperature. Do not shake. Do not use if solution is discolored or contains particulate matter. Prefilled syringe does not contain a preservative; discard unused portion.
Store at 2°C to 8°C (36°F to 46°F). Do not freeze. Do not expose to direct heat. Protect from light; do not expose to direct sunlight. Do not shake. Prefilled syringes may be stored up to 25°C (77°F) for a maximum of 14 days; after removal from refrigerator, use within 14 days or discard.
Vaccines (Live): Dupilumab may enhance the adverse/toxic effect of Vaccines (Live). Avoid combination
Immunologic: Antibody development (5% to 16%; neutralizing: 2% to 5%)
Local: Injection site reaction (6% to 18%)
1% to 10%:
Central nervous system: Insomnia (1%)
Gastrointestinal: Oral herpes simplex infection (4%), gastritis (2%), toothache (1%)
Hematologic & oncologic: Eosinophilia (≤2%)
Infection: Herpes simplex infection (2%)
Neuromuscular & skeletal: Arthralgia (3%)
Ophthalmic: Conjunctivitis (2% to 10%), eye pruritus (1%)
Respiratory: Oropharyngeal pain (2%)
<1%, postmarketing, and/or case reports: Anaphylaxis, dry eye syndrome, eosinophilic granulomatosis with polyangiitis, eosinophilic pneumonitis, erythema nodosum, hypersensitivity reaction, keratitis, serum sickness, serum sickness-like reaction, significant cardiovascular event, vasculitis
Concerns related to adverse effects:
• Hypersensitivity: Hypersensitivity reactions, including urticaria, rash, erythema nodosum, and serum sickness or serum sickness-like reactions, have been reported (rare); if signs/symptoms of a serious hypersensitivity reaction develop discontinue immediately and initiate appropriate treatment.
• Eosinophilia and vasculitis: In rare cases, patients may present with serious systemic eosinophilia, sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis, a condition which is often treated with systemic corticosteroid therapy. Monitor for eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy; especially upon reduction of oral corticosteroids. A causal association between dupilumab and these underlying conditions has not been established.
• Ocular effects: Conjunctivitis and keratitis have been reported; report new-onset or worsening eye symptoms to health care provider.
• Asthma: Discontinuation or adjustment of asthma medications in patients treated for atopic dermatitis or rhinosinusitis with comorbid asthma should not be done without consulting health care provider.
• Helminth infections: It is unknown if administration of dupilumab will influence a patient's response against parasitic infections; patients with known helminth infections were not studied. Therefore, patients with preexisting helminth infections should undergo treatment of the infection prior to initiation of dupilumab therapy. Patients who become infected during treatment and do not respond to anti-helminth therapy should discontinue dupilumab until the infection resolves.
Concurrent drug therapy issues:
• Corticosteroid therapy: Gradually taper systemic, topical, or inhaled corticosteroid therapy; do not discontinue corticosteroids abruptly following initiation of dupilumab therapy.
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
Dosage form specific issues:
• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.
• Appropriate use: Asthma: Therapy has not been shown to alleviate acute asthma exacerbations; do not use to treat acute bronchospasm or status asthmaticus.
• Appropriate use: Atopic dermatitis: Dupilumab may be used in combination with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but should be reserved for problem areas only (eg, face, neck intertriginous and genital areas).
• Immunogenicity: Dupilumab antibodies, including neutralizing antibodies, may develop; may be associated with lower serum dupilumab concentrations.
• Vaccines: Avoid the use of live vaccines in patients treated with dupilumab.
Monitor for signs/symptoms of hypersensitivity reactions and ocular adverse effects; signs of infection; pulmonary function in patients treated for asthma
Dupilumab is a monoclonal IgG antibody; IgG molecules are known to cross the placenta therefore exposure to the fetus during pregnancy may occur. Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of preeclampsia, preterm birth, low birth weight infants). Asthma should be closely monitored in pregnant women.
Data collection to monitor pregnancy and infant outcomes following exposure to dupilumab is ongoing. For additional information or to enroll pregnancies exposed to dupilumab, contact the registry at 1-877-311-8972 or https://mothertobaby.org/ongoing-study/dupixent/.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience injection site irritation, pharyngitis, or cold sores. Have patient report immediately to prescriber severe eye irritation, vision changes, eye pain, swollen glands, joint pain, dizziness, passing out, persistent fever, difficulty breathing, chest pain, shortness of breath, excessive weight gain, swelling of arms or legs, or burning or numbness feeling (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
More about dupilumab
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- 154 Reviews
- Drug class: interleukin inhibitors
Other brands: Dupixent